of the body. With an exclusive worldwide license from the Medical University of South Carolina (MUSC) for eight specific antibodies as well as the process to make additional fully-human antibodies to this target and worldwide exclusive licenses to the method of treating cancer with an anti-nucleolin antibody and the method for for the diagnosis and prognosis of malignant disease which includes the detection of nucleolin in the cell surface of a patient’s tumor cells tissue biopsy, they are focused on demonstrating preclinical proof of concept for their anti-nucleolin monoclonal antibodies. Research in their laboratories at the Charleston Innovation Center is designed to identify the most promising antibodies for subsequent in vivo studies that will establish preclinical efficacy and safety.